Roivant Sciences Files 8-K
Ticker: ROIV · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1635088
Sentiment: neutral
Topics: regulatory-filing, disclosure
TL;DR
Roivant Sciences filed an 8-K, standard procedure but keep an eye out for what's next.
AI Summary
Roivant Sciences Ltd. filed an 8-K on September 10, 2024, to report information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom, and its principal business address in Hamilton, Bermuda. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Roivant Sciences is making a regulatory disclosure and submitting financial exhibits, which is standard practice but may precede significant announcements.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate negative or positive events.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- September 10, 2024 (date) — Date of earliest event reported
- 7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom (location) — Address of Principal Executive Offices
- Hamilton HM11, Bermuda (location) — Business Address
FAQ
What is the primary purpose of this 8-K filing by Roivant Sciences Ltd.?
The primary purpose of this 8-K filing is to report information under Regulation FD Disclosure and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 10, 2024.
Where are Roivant Sciences Ltd.'s principal executive offices located?
Roivant Sciences Ltd.'s principal executive offices are located at 7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom.
What is the company's business address as listed in the filing?
The company's business address is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.
What is the SIC code for Roivant Sciences Ltd.?
The Standard Industrial Classification (SIC) code for Roivant Sciences Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-09-10 07:15:22
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
Filing Documents
- ef20035693_8k.htm (8-K) — 28KB
- ef20035693_ex99-1.htm (EX-99.1) — 20KB
- 0001140361-24-040650.txt ( ) — 188KB
- roiv-20240910.xsd (EX-101.SCH) — 4KB
- roiv-20240910_lab.xml (EX-101.LAB) — 21KB
- roiv-20240910_pre.xml (EX-101.PRE) — 16KB
- ef20035693_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclo sure. On September 10, 2024, Roivant Sciences Ltd. (the "Company") issued a press release announcing its previously undisclosed pipeline program mosliciguat, under development at Pulmovant. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROIVANT SCIENCES LTD. Date: September 10, 2024 By: /s/ Matt Maisak Name: Matt Maisak Title: Authorized Signatory